GLP-1 Drugs May Reach Only Half of Eligible Patients
Eli Lilly's CEO says structural barriers will cap GLP-1 weight-loss drug adoption at 40-50% of eligible patients, mirroring statin penetration rates.
obesity treatment
3 articles tagged "obesity treatment"
FDA Approves High-Dose Wegovy 7.2mg for Obesity in 2026
The FDA approved high-dose semaglutide 7.2mg (Wegovy) for obesity, showing 18.7% mean weight loss in Phase 3 trials amid new Trump administration drug pricing agreements.
By Sarah Tanaka
Oral Obesity Pill Phase 2 Results & Cholesterol Guidelines 2026
Structure Therapeutics reports 16% weight loss in Phase 2 oral GLP-1 trial, plus GSK's Arexvy expansion and new cholesterol guideline updates.